Mevlyq (Eribulin Mesylate)

Mevlyq (eribulin mesylate) is used in the treatment of solid tumours that are driven by rapid cell division.

• Metastatic breast cancer: improves progression‑free survival in patients previously treated with anthracyclines and taxanes.
• Unresectable or metastatic liposarcoma: provides disease control in patients with advanced soft‑tissue sarcoma.

• Eribulin mesylate binds to the plus ends of microtubules, preventing their elongation and thereby disrupting microtubule dynamics. This inhibition leads to a blockade of the G2‑M phase of the cell cycle, causing mitotic arrest and subsequent apoptosis of proliferating cancer cells. The drug’s action is independent of tubulin polymerization and results in selective cytotoxicity against rapidly dividing tumour cells.

Eribulin may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Neutropenia: reduced white blood cell count leading to infection risk.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: feeling of sickness often accompanied by vomiting.
• Peripheral neuropathy: tingling or numbness in the hands and feet.

Serious or Rare Side Effects

• Febrile neutropenia: fever with low neutrophil count requiring urgent care.
• Pulmonary toxicity: difficulty breathing or interstitial lung disease.
• Severe hepatic dysfunction: marked elevation of liver enzymes or liver failure.

When using Mevlyq, clinicians should observe several safety measures to minimize risk.

• Monitor blood counts: perform regular complete blood count assessments.
• Assess liver function: check hepatic enzymes before and during therapy.
• Evaluate cardiac status: perform baseline ECG and monitor for arrhythmias.
• Avoid in severe neutropenia: do not administer if absolute neutrophil count is critically low.
• Use caution with pre‑existing neuropathy: adjust dosing if peripheral nerve symptoms are present.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Eribulin can interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid)

• Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase eribulin exposure.
• Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce eribulin plasma levels.
• Anticoagulants (e.g., warfarin): monitor coagulation parameters for bleeding risk.
• Drugs causing peripheral neuropathy (e.g., vincristine): increase likelihood of nerve toxicity.